• Réf. :HematoStat.net ; 2 (7) : R52   Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized […]

    Published On: 12 July 2022